Calmark receives Notice of Allowance regarding patent in USA

Calmark Sweden AB (publ) announces today that the US Patent Office ("USPTO") has issued a so-called Notice of Allowance regarding Calmark's test cassette and the construction of volume control, so-called 'Exact fill'

The patent with the title "Exact fill" and application number 17/254609 covers the design of the test cassette for volume control of the blood sample amount. The patent provides protection until 2040. The Notice of Allowance means that the USPTO will approve the company's patent application.

Including the new patent, Calmark owns 20 patents and 11 design protections regarding both the instrument and the disposable test in important markets.

"Today's announcement is gratifying," says Anna Söderlund, CEO of Calmark. "For Calmark, it is strategically important to have broad patent protection for the company's technologies and methods, it protects us against competition and plagiarism. We are continuously working on patenting our innovations.”

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.